Recurrent primary biliary cirrhosis after liver transplantation - The disease and its management

Ian Schreibman, Arie Regev

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by the destruction of interlobular and septal bile ducts that can lead to fibrosis and cirrhosis. Orthotopic liver transplantation (OLT) remains the definitive treatment for decompensated liver disease secondary to PBC. An estimated 10% to 40% of patients develop clinical, biochemical, and histologic changes consistent with recurrent PBC after OLT. However, the presence of recurrent PBC does not appear to affect either graft or patient survival rates. There is conflicting evidence regarding the effect of specific immunosuppressant medications (eg, tacrolimus vs cyclosporine) on the risk of recurrent PBC. Most experts favor the use of ursodeoxycholic acid (UDCA) for recurrent PBC given its beneficial effect in patients with pretransplant PBC and its improvement of biochemical markers in the posttransplant setting. However, despite its potential benefit, there is no evidence that UDCA improves graft or patient survival in recurrent PBC.

Original languageEnglish (US)
Article number30
JournalMedGenMed Medscape General Medicine
Volume8
Issue number2
StatePublished - May 10 2006

Fingerprint

Biliary Liver Cirrhosis
Disease Management
Liver Transplantation
Ursodeoxycholic Acid
Liver Diseases
Fibrosis
Transplants
Tacrolimus
Immunosuppressive Agents
Bile Ducts
Cyclosporine
Survival Rate
Biomarkers
Survival

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{6ade409fd24f4802b63671134d7a90aa,
title = "Recurrent primary biliary cirrhosis after liver transplantation - The disease and its management",
abstract = "Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by the destruction of interlobular and septal bile ducts that can lead to fibrosis and cirrhosis. Orthotopic liver transplantation (OLT) remains the definitive treatment for decompensated liver disease secondary to PBC. An estimated 10{\%} to 40{\%} of patients develop clinical, biochemical, and histologic changes consistent with recurrent PBC after OLT. However, the presence of recurrent PBC does not appear to affect either graft or patient survival rates. There is conflicting evidence regarding the effect of specific immunosuppressant medications (eg, tacrolimus vs cyclosporine) on the risk of recurrent PBC. Most experts favor the use of ursodeoxycholic acid (UDCA) for recurrent PBC given its beneficial effect in patients with pretransplant PBC and its improvement of biochemical markers in the posttransplant setting. However, despite its potential benefit, there is no evidence that UDCA improves graft or patient survival in recurrent PBC.",
author = "Ian Schreibman and Arie Regev",
year = "2006",
month = "5",
day = "10",
language = "English (US)",
volume = "8",
journal = "MedGenMed Medscape General Medicine",
issn = "1531-0132",
publisher = "Medscape Health Network",
number = "2",

}

Recurrent primary biliary cirrhosis after liver transplantation - The disease and its management. / Schreibman, Ian; Regev, Arie.

In: MedGenMed Medscape General Medicine, Vol. 8, No. 2, 30, 10.05.2006.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recurrent primary biliary cirrhosis after liver transplantation - The disease and its management

AU - Schreibman, Ian

AU - Regev, Arie

PY - 2006/5/10

Y1 - 2006/5/10

N2 - Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by the destruction of interlobular and septal bile ducts that can lead to fibrosis and cirrhosis. Orthotopic liver transplantation (OLT) remains the definitive treatment for decompensated liver disease secondary to PBC. An estimated 10% to 40% of patients develop clinical, biochemical, and histologic changes consistent with recurrent PBC after OLT. However, the presence of recurrent PBC does not appear to affect either graft or patient survival rates. There is conflicting evidence regarding the effect of specific immunosuppressant medications (eg, tacrolimus vs cyclosporine) on the risk of recurrent PBC. Most experts favor the use of ursodeoxycholic acid (UDCA) for recurrent PBC given its beneficial effect in patients with pretransplant PBC and its improvement of biochemical markers in the posttransplant setting. However, despite its potential benefit, there is no evidence that UDCA improves graft or patient survival in recurrent PBC.

AB - Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by the destruction of interlobular and septal bile ducts that can lead to fibrosis and cirrhosis. Orthotopic liver transplantation (OLT) remains the definitive treatment for decompensated liver disease secondary to PBC. An estimated 10% to 40% of patients develop clinical, biochemical, and histologic changes consistent with recurrent PBC after OLT. However, the presence of recurrent PBC does not appear to affect either graft or patient survival rates. There is conflicting evidence regarding the effect of specific immunosuppressant medications (eg, tacrolimus vs cyclosporine) on the risk of recurrent PBC. Most experts favor the use of ursodeoxycholic acid (UDCA) for recurrent PBC given its beneficial effect in patients with pretransplant PBC and its improvement of biochemical markers in the posttransplant setting. However, despite its potential benefit, there is no evidence that UDCA improves graft or patient survival in recurrent PBC.

UR - http://www.scopus.com/inward/record.url?scp=33646254131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646254131&partnerID=8YFLogxK

M3 - Article

C2 - 16926769

AN - SCOPUS:33646254131

VL - 8

JO - MedGenMed Medscape General Medicine

JF - MedGenMed Medscape General Medicine

SN - 1531-0132

IS - 2

M1 - 30

ER -